Prostaglandin E2 regulates pancreatic stellate cell activity via the EP4 receptor

Pancreas

Volumn 42, Issue 3, 2013, Pages 467-474

  Charo, Chantale ^a   Holla, Vijaykumar ^a   Arumugam, Thiruvengadam ^a   Hwang, Rosa ^a   Yang, Peiying ^a   Dubois, Raymond N ^a   Menter, David G ^a   Logsdon, Craig D ^a   Ramachandran, Vijaya ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

EP4 receptor; Pancreatic cancer; Pancreatic stellate cells; PGE2

Indexed keywords

6 ISOPROPOXY 9 OXO 2 XANTHENECARBOXYLIC ACID; CYCLOOXYGENASE 2; ICOSANOID; MATRIX METALLOPROTEINASE; ONOAE3208; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN E2; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; SC18220; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; 4 (4 CYANO 2 (2 (4 FLUORONAPHTHALEN 1 YL)PROPIONYLAMINO)PHENYL)BUTYRIC ACID; 4-(4-CYANO-2-(2-(4-FLUORONAPHTHALEN-1-YL)PROPIONYLAMINO)PHENYL)BUTYRIC ACID; ARYLBUTYRIC ACID DERIVATIVE; COLLAGEN TYPE 1; COLLAGEN TYPE I, ALPHA 1 CHAIN; GELATINASE A; GELATINASE B; NAPHTHALENE DERIVATIVE;

ARTICLE; CELL ACTIVATION; CELL ACTIVITY; CELL ASSAY; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CYSTIC FIBROSIS; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIQUID CHROMATOGRAPHY; PANCREATIC STELLATE CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TANDEM MASS SPECTROMETRY; CELL CULTURE; CELL MOTION; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION; GENETICS; METABOLISM; RNA INTERFERENCE; TUMOR CELL CULTURE;

CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; COLLAGEN TYPE I; CYCLOOXYGENASE 2; DINOPROSTONE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NAPHTHALENES; PANCREATIC STELLATE CELLS; PHENYLBUTYRATES; RECEPTORS, PROSTAGLANDIN E, EP4 SUBTYPE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR CELLS, CULTURED;

EID: 84875465249     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e318264d0f8     Document Type: Article

References (42)

1. Masamune A, Watanabe T, Kikuta K, et al. Roles of pancreatic stellate cells in pancreatic inflammation and fibrosis. Clin Gastroenterol Hepatol. 2009;7:S48-S54.
2. Vonlaufen A, Joshi S, Qu C, et al. Pancreatic stellate cells and pancreatic cancer cells: An unholy alliance. Cancer Res. 2008;68:2085-2093.
3. Apte MV, Wilson JS. Mechanisms of pancreatic fibrosis. Dig Dis. 2004;22:273-279.
4. Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009;324:1457-1461.
5. Apte MV, Haber PS, Darby SJ, et al. Pancreatic stellate cells are activated by pro inflammatory cytokines: Implications for pancreatic fibrogenesis. Gut. 1999;44:534-541.
6. Schlosser W, Schlosser S, Ramadani M, et al. Cyclooxygenase-2 is overexpressed in chronic pancreatitis. Pancreas. 2002;25:26-30.
7. Tucker ON, Dannenberg AJ, Yang EK. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res. 1999;59:987-990.
8. Robert A, Nezamis JE, Lancaster C, et al. Cytoprotection by prostaglandins in rats. Prevention of gastric necrosis produced by alcohol, HCl, NaOH, hypertonic NaCl, and thermal injury. Gastroenterology. 1979;77:433-443.
9. Wang D, Dubois RN. The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene. 2010;29:781-788.
10. Krysan K, Reckamp KL, Sharma S, et al. The potential and rationale for COX-2 inhibitors in lung cancer. Anticancer Agents Med Chem. 2006;6:209-220.
11. Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci. 2000;30:3-21.
12. Wu WK, Sung JJ, Lee CW, et al. Dysregulation of cellular signaling in gastric cancer. Cancer Lett. 2010;295:7-16.
13. Kokawa A, Kondo H, Gotoda T, et al. Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors. Cancer. 2001;91:333-338.
14. Koshiba T, Hosotani R, Miyamoto Y, et al. Immunohistochemical analysis of cyclooxygenase-2 expression in pancreatic tumors. Int J Pancreatol. 1999;26:69-76.
15. Merati K, Saidaty M, Andea A, et al. Expression of inflammatory modulator COX-2 in pancreatic ductal adenocarcinoma and its relationship to pathologic and clinical parameters. Am J Clin Oncol. 2001;24:447-452.
16. Maitra A, Ashfaq R, Gunn CR, et al. Cyclooxygenase 2 expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia: An immunohistochemical analysis with automated cellular imaging. Am J Clin Pathol. 2002;118:194-201.
17. Colby JK, Klein RD, McArthur MJ, et al. Progressive metaplastic and dysplastic changes in mouse pancreas induced by cyclooxygenase-2 overexpression. Neoplasia. 2008;10:782-796.
18. Farrow B, Rowley D, Dang T, et al. Characterization of tumor-derived pancreatic stellate cells. J Surg Res. 2009;157:96-102.
19. Menke A, Adler G. TGFbeta-induced fibrogenesis of the pancreas. Int J Gastrointest Cancer. 2002;31:41-46.
20. Zhang W, Erkan M, Abiatari I, et al. Expression of extracellular matrix metalloproteinase inducer (EMMPRIN/CD147) in pancreatic neoplasm and pancreatic stellate cells. Cancer Biol Ther. 2007;6: 218-227.
21. Hwang RF, Moore T, Arumugam T, et al. Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res. 2008;68:918-926.
22. Aoki H, Ohnishi H, Hama K, et al. Cyclooxygenase-2 is required for activated pancreatic stellate cells to respond to proinflammatory cytokines. Am J Physiol Cell Physiol. 2007;292:C259-C268.
23. Xu L, Li YM, Yu C, et al. Expression of p53, p16 and COX-2 in pancreatic cancer with tissue microarray. Hepatobiliary Pancreat Dis Int. 2006;5:138-142.
24. Yoshida S, Ujiki M, Ding XZ, et al. Pancreatic stellate cells (PSCs) express cyclooxygenase-2 (COX-2) and pancreatic cancer stimulates COX-2 in PSCs. Mol Cancer. 2005;4:27.
25. Ma X, Kundu N, Rifat S, et al. Prostaglandin E receptor EP4 antagonism inhibits breast cancer metastasis. Cancer Res. 2006;66:2923-2927.
26. Fujita H, Ohuchida K, Mizumoto K, et al. Tumor-stromal interactions with direct cell contacts enhance proliferation of human pancreatic carcinoma cells. Cancer Sci. 2009;100:2309-2317.
27. ApteMV, Pirola R,Wilson J. New insights into alcoholic pancreatitis and pancreatic cancer. J Gastroenterol Hepatol. 2009;24:S51-S56.
28. Masamune A, Shimosegawa T. Signal transduction in pancreatic stellate cells. J Gastroenterol. 2009;44:249-260.
29. Okami J, Yamamoto H, Fujiwara Y, et al. Overexpression of cyclooxygenase-2 in carcinoma of the pancreas. Clin Cancer Res. 1999;5:2018-2024.
30. Albazaz R, Verbeke CS, Rahman SH, et al. Cyclooxygenase-2 expression associated with severity of PanIN lesions: A possible link between chronic pancreatitis and pancreatic cancer. Pancreatology. 2005;5:361-369.
31. Arjona-Sanchez A, Ruiz-Rabelo J, Perea MD, et al. Effects of capecitabine and celecoxib in experimental pancreatic cancer. Pancreatology. 2010;10:641-647.
32. Funahashi H, Satake M, Dawson D, et al. Delayed progression of pancreatic intraepithelial neoplasia in a conditional Kras (G12D) mouse model by a selective cyclooxygenase-2 inhibitor. Cancer Res. 2007;67:7068-7071.
33. Raut CP, Nawrocki S, Lashinger LM, et al. Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts. Cancer Biol Ther. 2004;3:1217-1224.
34. Dajani EZ, Islam K. Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man. J Physiol Pharmacol. 2008;59:117-133.
35. El-Rayes BF, Zalupski MM, Shields AF, et al. A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer. Invest New Drugs. 2005;23:583-590.
36. Ferrari V, Valcamonico F, Amoroso V, et al. Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: A phase II trial. Cancer Chemother Pharmacol. 2006;57:185-190.
37. Lipton A, Campbell-Baird C, Witters L, et al. Phase II trial of gemcitabine, irinotecan, and celecoxib in patients with advanced pancreatic cancer. J Clin Gastroenterol. 2010;44:286-288.
38. Pino MS, Milella M, Gelibter A, et al. Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers. Oncology. 2009;76:254-261.
39. Xiong HQ, Plunkett W, Wolff R, et al. A pharmacological study of celecoxib and gemcitabine in patients with advanced pancreatic cancer. Cancer Chemother Pharmacol. 2005;55:559-564.
40. Pino MS, Nawrocki ST, Cognetti F, et al. Prostaglandin E2 drives cyclooxygenase-2 expression via cyclic AMP response element activation in human pancreatic cancer cells. Cancer Biol Ther. 2005;4:1263-1269.
41. Katoh H, Hosono K, Ito Y, et al. COX-2 and prostaglandin EP3/EP4 signaling regulate the tumor stromal proangiogenic microenvironment via CXCL12-CXCR4 chemokine systems. Am J Pathol. 2010;176:1469-1483.
42. Doherty GA, Byrne SM, Molloy ES, et al. Proneoplastic effects of PGE2 mediated by EP4 receptor in colorectal cancer. BMC Cancer. 2009;9:207.